Showing results (191-200 of 258) with videos related to

Sort By:
Pageof 26
The Oncologist|April 22, 2025
Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumorsNai-Jung Chiang, Jih-Hsiang Lee, Ming-Huang Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencingYen-Ting Lin, Chi-Lu Chiang, Jen-Yu Hung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2013
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.
Plos One|July 7, 2011
Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cellsYun-Ju Chen, Wei-Chien Huang, Ya-Ling Wei, et al.
The Lancet. Oncology|February 7, 2020
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2023
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.
The Lancet. Oncology|March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialVincent A Miller, Vera Hirsh, Jacques Cadranel, et al.
JCO Global Oncology|September 30, 2024
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, et al.
The Journal of Molecular Diagnostics : JMD|June 5, 2020
Electric Field-Induced Release and Measurement (EFIRM): Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and SalivaMichael Tu, Jordan Cheng, Yi-Lin Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2023
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA TrialThomas John, Christian Grohé, Jonathan W Goldman, et al.
Pageof 26